Clarivate Plc (CLVT) Earnings Call Transcript & Summary

July 29, 2026

New York Stock Exchange US Industrials Professional Services earnings 36 min

Earnings Call Speaker Segments

Mark Donohue

executive
#1

Thanks so much, and hello everybody. I appreciate all of you taking the time to be with us on this call covering Clarivate's results for the second quarter of 2026. Just so everyone is aware, we are recording this call and streaming it over the web, and the content is protected as Clarivate's copyrighted material. Republishing any portion of what is said here, whether fully or partially, requires Clarivate's written permission beforehand. You can find the slide deck that goes along with this call posted in the Investor Relations area of our site. While we speak today, we might share some forward-looking statements as defined under the relevant securities regulations. Those statements carry known and unknown risks, uncertainties and other elements that could lead the business's real results, performance or accomplishments, or shifts in Clarivate's business, to end up materially different from what those forward-looking statements anticipate, express or suggest. Details on what might push actual outcomes and performance materially away from expectations appear in Clarivate's SEC filings and on our website. We'll also be talking about non-GAAP or adjusted figures. Clarivate views non-GAAP results as helpful for making our continuing operating performance easier to understand, but they only supplement GAAP financial measures and shouldn't be viewed by themselves or as a replacement for them. You can find how these measures reconcile to GAAP in our earnings release and the supplemental presentation posted on our site. Joining me on the line are Matti Shem Tov, our Chief Executive Officer; Jonathan Collins, our Chief Financial Officer; and Michael Easton, our Chief Accounting Officer. Once we finish our prepared comments, we'll take your questions. With all that said, I'm happy to hand things over to Matti.

Matti Shem Tov

executive
#2

Hello to all of you, and I appreciate you being here with us. Today's main points are simple and clear. Our promises are being fulfilled, and the groundwork is now set for us to speed up organic growth. Over the quarter, we moved our AI innovation roadmap forward, increased organic ACV compared with the same period last year, kept our cost management tight, and made our balance sheet stronger by reducing debt. Shareholders will gain additional long-term value from these steps. Throughout the second quarter, we made ongoing headway across the company. Organic ACV growth rose to 1.5%, while profit margin has widened beyond 42%. Looking at each segment, both Academia & Government and Life Sciences & Healthcare posted 2% organic ACV growth. One indication of ongoing headway is the move away from transactional revenue toward recurring revenue. As our attention centers on subscription revenue, we anticipate this will keep happening over the next several quarters. Within the Intellectual Property segment, recurring organic revenue got better, reaching flat during the quarter; our expectation of a return to growth in the second half remains unchanged. We reached important innovation milestones, among them the launch of two new agentic AI offerings, Nexus Connect and IP-1, about which I will say more shortly. Additionally, during early July, we revealed our agreement to divest our Life Sciences & Healthcare segment, which sharpens our concentration on AI-driven transformative intelligence and improves our financial profile. I will provide further details on this in a moment as well. These outcomes demonstrate consistent implementation of the value creation plan that we started in late 2024; we are proceeding with urgency. The headway we have made is evident. Our investments are smart, our operations are more disciplined, and our resources go toward the growth opportunities with the greatest value. What sets Clarivate apart in this field is our capacity to bring AI to bear on highly curated proprietary datasets assembled and honed across decades. Consequently, we think we are on a trajectory to increase our growth rate over the coming couple of years. Now to the A&G segment. Our approach is to serve as the trusted layer connecting AI and research. This involves leveraging cloud-based proprietary data, domain expertise, and local solutions so institutions can make sounder decisions with confidence and transparency. This quarter, we released Web of Science Research Intelligence around the world. It is an AI-native platform for research strategy, impact, and funding. More than 50 development partners and early adopters spanning 20 countries helped shape it. Publisher-neutral Web of Science data grounds the insights it produces. It offers complete editorial provenance. A pipeline worth several million dollars in annual contract value has already come out of this, and as of now, 77 paying customers have been secured. That's a great example of how new AI-based offerings are adding to our pipeline. In addition, we launched Nexus Connect, an AI-native gateway that provides one connector for universities alongside AI chat agents such as ChatGPT and Claude; through it, students and researchers can access scholarly resources and services, and it works smoothly across several AI platforms to make research better. The key point is that we are embedding Clarivate's proprietary intelligence into the research workflows that the academic community is already using. New revenue streams are resulting from that. With the IP segment, we're applying the very same innovative mindset. We shared news that IP-1 is in development — a single, unified AI platform. It brings together AI agents designed for specific purposes, along with private, trusted proprietary assets and distinctive expertise. Thanks to the agentic AI features of this platform, IP professionals can get quick answers to patent and trademark intelligence questions, and they can also make complicated everyday workflows simpler across the entire IP lifecycle. Building IP-1 is happening hand in hand with top corporate IP teams and law firms. We're eager to discuss it in the quarters ahead; market validation for our IP innovation keeps growing. Recently, at the 2026 CODiE awards, RiskMark took the title of best AI tool for lawyers. The honor came its way because the tool applies predictive and generative AI to shrink trademark risk evaluation from a matter of hours to just minutes. That marks the second time the industry has recognized this product, following the 2025 LegalTech Predictive AI Solution of the Year award. We were glad in June to bring Simon Webster aboard as president of our IP segment. Within the worldwide IP ecosystem, Simon has established himself as a strong leader, bringing over two decades of experience, among it serving as CEO of CPA Global, a company Clarivate picked up in late 2020. During his tenure at CPA Global, that organization achieved mid-single-digit compounded annual organic growth. Within IP, our focus areas are keeping customers across both annuities and software, ramping up commercial intensity, and speeding up AI innovation backed by data assets we own exclusively. A key point: there are real points of distinction in this business. We have scale, trusted ties with top law firms and blue-chip corporate IP teams, a robust recurring annuity and renewal engine, and unique proprietary content. Taken together with disciplined execution under Simon's leadership, we think this strength puts IP in position to deliver better results down the road. As we've said previously, back in early July we announced a deal to sell our Life Sciences & Healthcare segment to Altaris; that represents a significant move in our portfolio rationalization work and is a plain illustration of the VCP in action. With this deal, we become a leaner organization built around subscriptions as our primary offering. Our operations get simpler, and we gain the ability to concentrate spending on specific areas of organic growth. Beyond that, the deal upgrades what Clarivate earns its money from. Looking at pro forma figures, the share of revenue that repeats rises from 89% to roughly 92%, which means better forecasting, stronger customer stickiness, and clearer sight lines into cash flow. The net proceeds are earmarked for paying down debt. Doing so pushes out our average maturity date, puts our balance sheet in a stronger position, and gives us more financial room to maneuver, which in turn lets us create additional value for shareholders. Please turn with me to slide 12. I'll take you through what we've accomplished since we kicked off the value creation plan in late 2024, beginning with efforts to optimize our business model. Our revenue mix has moved in a significant way toward a recurring, subscription-based model. That gives us better visibility and predictability, along with a higher-quality base to grow from. In the same way, we've improved how we go to market, sharpening both our selling methods and the service we give customers. There's more momentum now in our recurring business, and the groundwork we've set for future bookings is more solid. On top of that, we've accelerated AI innovation across the entire company. We have a strong and growing lineup of new AI-driven products, which increases the value customers get and boosts our competitive position. We've also streamlined our offerings. We made intentional choices to divest businesses outside our core, and we've announced several of those sales. As a result, our capital and attention are now concentrated on our two biggest markets, which brings me to my next point: driving faster organic growth. With a tighter portfolio, recurring revenue of better quality, an improved go-to-market operation, promising new offerings, and a stronger balance sheet, we expect recurring organic growth to improve sequentially in the back half of 2026, and that trajectory should continue into 2027. We are directing funds toward the right opportunities, and our belief in our ability to execute, accelerate organic growth, and create long-term shareholder value has never been stronger. I'll hand things to Jonathan so he can walk through this quarter's results in more detail.

Jonathan Collins

executive
#3

Thanks, Matti. On slide 14, you'll see a summary of how we performed in Q2 and the first six months versus the equivalent stretches a year ago. Revenue for the second quarter came in at $587 million, which lifted our first-half top line to just under $1.2 billion. Year-over-year movement in the quarter reflected inorganic divestitures, a decline in organic transactional revenue, and a slight currency headwind, partly countered by growth in organic recurring revenue. Our net loss for Q2 stood at $269 million. Versus the comparable period a year earlier, that swing came solely from a non-cash impairment charge stemming from the definitive agreement we signed to sell off the LS&H segment. Adjusted diluted EPS for Q2 rose $0.01 year over year, reaching $0.19, and that put the first half at $0.38 — a 19% gain versus the equivalent stretch a year ago. Operating cash flow for the quarter totaled $99 million. The year-over-year difference came from reduced adjusted EBITDA tied to the divestitures and currency effects, since lower interest expense got offset by greater working capital needs driven by the timing of receipts and disbursements. Now please join me on page 15, where we'll dig into what drove the Q2 top- and bottom-line shifts versus a year ago. Three main factors explain the year-over-year movement. To start, organic revenue fell $9 million, since recurring growth of roughly 1.5% only partly made up for weaker transactional revenue. We offset the revenue hit via cost efficiencies, so the profit effect was negligible. Next, the businesses being divested cut revenue by $24 million, yet cost savings from the wind-downs mostly made up for that, producing a net $7 million drop in adjusted EBITDA. Lastly, although the top line barely moved because of currency, we absorbed an adjusted EBITDA headwind of $7 million from appreciation in a basket of foreign currencies relative to the U.S. dollar. All told, tight cost discipline let us hold our adjusted EBITDA margin steady versus the same period a year ago even with the revenue decline. Now please join me on page 16 for the matching review of the first half. Although organic revenue is down $5 million versus a year ago, cost discipline has fully offset the effect and added $8 million to adjusted EBITDA. The strategic divestitures cut revenue by $49 million but widened profit margins, producing just a $10 million decline in adjusted EBITDA. In the comparable stretch a year earlier, the U.S. dollar was weaker versus the basket of foreign currencies, generating a $12 million currency tailwind on the top line but creating a $5 million profit headwind, because transaction gains booked last year did not repeat this year. On the whole, the strategic divestitures plus tight cost management produced margin expansion of close to a full percentage point during the first half, and we expect that improving trend to carry into the second half. If everyone could move with me to page 17, we'll look at the way adjusted EBITDA turned into free cash flow, and how we kept deploying capital with discipline to make the balance sheet even stronger. In the second quarter, free cash flow came in at $44 million, down $6 million versus the prior-year period. That swing reflected higher working capital, mostly from the timing of collections and payments, partly offset by reduced interest and capital spending. With that free cash flow plus surplus cash on hand, we bought back an additional $75 million of bonds maturing in 2028 at a modest discount of roughly 3%, which brought first half debt reduction to $218 million. Now let's move to page 18, where you can see our full-year financial guidance ranges, unchanged from what we first gave in February, reaffirmed in April, and then refined a few weeks ago when we announced the agreement to sell the LS&H segment. As of today, we're refining our indications within those ranges a bit further, mainly to capture the impact tied to the LS&H divestiture, which we anticipate closing by the end of the year; for modeling purposes, instead of estimating a closing date, assume the transaction closes at year-end. Should it close earlier, we'll adjust the guidance at that point to reflect the impact. Our organic annual contract value is now expected in the lower half of the range, entirely because LS&H will be excluded from this metric in the second half as it shifts to discontinued operations. Importantly, we anticipate A&G approaching 3% and the IP segment returning to growth by year-end, blending to roughly 2.25% growth. We continue to expect recurring organic growth of about 1.5%, near the midpoint of our range, which is still an improvement of almost a percentage point over last year. Revenue is now projected just below the midpoint of the range at $2.35 billion, due entirely to foreign exchange, and our organic recurring revenue mix will be above the high end of the original range at about 92% as LS&H moves to discontinued operations. Adjusted EBITDA should stay at just over $1 billion, for a profit margin of nearly 43% at the midpoint of the range. We still expect adjusted diluted EPS to grow about 9% at the midpoint of the range, to $0.75. Lastly, free cash flow is now likely to land at the low end of the range, since we've contemplated the full transaction cost to close the LS&H divestiture and also incorporated additional restructuring costs to achieve incremental cost savings so we recognize the full benefit next year. Now please turn with me to page 19 for a reminder of the full-year top and bottom line changes we expect compared to last year. Our forecast still calls for adjusted EBITDA margin to rise roughly 200 basis points, supported by a comeback in organic growth, ongoing cost control, and finishing the strategic divestitures. We expect organic growth around 1%, powered mainly by subscription revenue gains as ACV keeps accelerating. Plans are already set to capture cost savings that entirely counter inflation, producing $25 million in added profit. That represents roughly one-third of the margin improvement. The divestitures outside our core should cut revenue by $125 million this year, while we trim operating expenses by roughly $100 million, generating a profit effect of approximately $25 million and supplying the other two-thirds of the margin gain. Keep in mind, our outlook presumes we hold the LS&H business through year-end, and should the deal close sooner, we would revise guidance at that point. We now expect foreign exchange to be basically unchanged versus last year, which is the sole adjustment to our revenue and adjusted EBITDA outlook within their respective ranges. Now please join me on page 20 as we walk through how revenue and profits should be seasonally distributed this year. We have updated this using our first half results.

Jonathan Collins

executive
#4

We still expect the business to pick up organically during the latter six months of the year, driven by better retention along with new business sales. As we progress through the rest of the year, that organic growth, plus additional cost efficiencies and the gain from the strategic disposals, ought to bend profit margins upward. Q3 revenue should be lower because of seasonality, then Q4 should come in higher, reflecting the usual pattern for patent and trademark renewals and transactional revenues. Now please go with me to page 21, where we'll walk through how we see the more than $1 billion of adjusted EBITDA turning into free cash flow, and how we intend to deploy that capital together with the proceeds from the LS&H divestiture to bring our debt down by roughly $900 million this year. Because of transaction costs we'll take on when the LS&H divestiture closes, our expectation now is that free cash flow will be flat versus last year, though the bulk of that one-time cost, close to $70 million, won't repeat next year; we still expect cash interest to come in about $20 million better than last year thanks to the debt we paid down last year and this year. Cash taxes should still land $5 million to $10 million above last year, mostly because of the new corporate tax in Jersey. Expect the working capital change this year to be a use of roughly $25 million, mainly from incentive compensation payments; we also anticipate a $10 million benefit tied to lower impaired contractual costs shown on the other row; and although we stay committed to investing in product innovation, the disposals and cost efficiencies should improve capital spending by roughly $20 million. On capital allocation, our plan is to take the free cash flow we generate in the second half of the year and the proceeds from the LS&H divestiture and use them to retire notes due in the next few years. I'll now hand the call back to Matti for some closing remarks before Q&A.

Matti Shem Tov

executive
#5

Prior to opening the floor for questions, I'd like to address the other item we announced today: Michael Easton will become our next chief financial officer, taking on the role as of August 8. A number of you are already familiar with Michael. He currently holds the position of chief accounting officer and sits on our senior leadership team. He's highly respected and carries over 25 years of experience in finance and leadership. Michael possesses a thorough grasp of our operations and has played a pivotal part in bolstering financial discipline, governance, and operational execution throughout Clarivate. His priorities will include speeding up growth, boosting profitability, enhancing free cash flow generation and preserving disciplined capital allocation. I'd like to express gratitude to Jonathan for the leadership he has shown. Throughout his time here, he has delivered numerous significant contributions to our company. He led the successful integration of the three acquisitions that make up Clarivate today, establishing the segment operating structure in place now and reshaping the finance organization. On a personal note, over the past two years, he has served as a valuable partner to me in driving the VCP forward, striving to raise profitability and reinforce our balance sheet. I extend my best wishes to Jonathan for every success ahead. Operator, let's begin the Q&A portion now.

Scott Wurtzel

analyst
#6

Hi, everyone. Morning, and I appreciate you answering my questions. I just wanted to ask about the fact that you mentioned some timing regarding renewals that might have had an effect on ACV growth in the quarter. Is any of that tied to sales cycles running longer? And is there anything we should anticipate carrying over into the back half of the year?

Jonathan Collins

executive
#7

Hi, morning, Scott. Appreciate the question. Our Q2 and first half results, as we see it, match what we had initially anticipated. To remind everybody, we highlighted the same thing as page 20 in Q1, saying we anticipated a decline in recurring organic growth for Q2. Subscriptions played a role in that. So when it comes to ACV, we've kept moving forward across the past six quarters. It won't always follow a straight line. Even so, renewal rates remain robust, and there are solid chances for new products to turn into sales. Renewal timing is something that shows up in the business every so often. Therefore, we don't view it as the renewal cycle getting stretched out, and organic ACV growth of roughly 1.5% at the close of June broadly matches our first half organic growth for subscription revenues of approximately 1.2%. So overall, we're where we thought we'd be. As we also point out on page 20 in the current quarter's deck, we anticipate ACV and organic recurring revenue will inflect during the back half of the year; we have strong visibility into that. Right now, at this stage of the year, the A&G business, as of the close of July, has 75% of this year's business already secured. Quite similar to what we observed at this same point a year ago. Autumn represents a key renewal cycle, but we're already far along, and we have strong visibility for the back half of the year. Appreciate the question, Scott.

Toni Kaplan

analyst
#8

Thanks a lot. I wanted to hear your thoughts on the MCP opportunity — which kinds of clients do you expect will lean more toward using your data through MCP, which segments, and so on. Also, how do you see it adding to growth, and does it come with the subscription, or do customers pay extra for it? And Jonathan, congrats on your new role. Thanks, Jonathan.

Matti Shem Tov

executive
#9

Yes, I'll handle this one. Appreciate it, Toni. I need to step back and look at the bigger picture regarding the AI innovation we're pursuing; our focus is strong. From when I came aboard, from when we launched the — the VCP, we've been executing on 19 separate initiatives. On the side of external and new products we're bringing out. We're extremely, extremely happy with how things have gone so far. We view AI enablement of what we already sell. It brings in revenue from new logos, new offerings, new returns, better retention, and I believe it also lets us apply some AI-specific pricing to new offerings. So fresh revenue generation or a fresh revenue stream; take Web of Science Research Intelligence, clearly a revenue, a fresh revenue stream. Alma Specto, a fresh revenue stream. IP-1, which I've discussed, and we're really enthusiastic about IP-1. Clearly a fresh revenue stream. Nexus Connect, one more product from A&G that involves MCP; and we find that customers across the three segments, Life Sciences included, are the ones consuming our data, our proprietary data. Whether that's straight from us via our UX or a new AI-enabled offering, or through their own systems, there's a tendency among some of the larger customers who want us to embed our capabilities, MCP capabilities, into their own, you know, corporate AI product, and that's why you're seeing more of our product whether it's embedded into Anthropic, ChatGPT, and other generic LLMs. Generally speaking, larger customers want the ability to embed this suite via MCP. Smaller customers might prefer to use it inside our environment; but it's still early days on the whole; we're very happy with the momentum we have bringing in AI, whether our own native or embedding our proprietary data into the customer's MCP environment basically, as a corporate AI infrastructure.

Jonathan Collins

executive
#10

Thanks.

Manav Patnaik

analyst
#11

Thanks, and congrats to you, Jonathan and Michael, on the new positions. My question concerns what's expected for organic growth acceleration — I believe that's 100 basis points sequentially? Could you expand on that a bit, in case it differs for Academia & Government versus the IP side? And then, looking ahead to 2027, maybe just: does that 100 basis points apply to the entire year in 2027 too, or how should we frame it?

Matti Shem Tov

executive
#12

We feel quite good about both segments; we've got visibility and building momentum in IP too. In Q2, recurring is back to flat. For IP, we expect recurring to get better during the back half of the year as well. With strong new momentum. And at this point, it's truly worth calling out that Simon has rejoined Clarivate. His time in the industry spans 20 years. He was generous enough to return and back us up. All his IP know-how and expertise will be applied toward speeding up progress on the IP turnaround. So we do think IP will turn around more quickly with Simon aboard, along with the excellent assets we hold in annuity, software and intelligence, plus the AI innovation I referenced. As you know, I brought up RiskMark as a product; it has taken three awards. I'm also pleased about IP-1. IP-1 isn't merely intelligence. IP-1 is actually an agentic environment in which IP professionals. Essentially, we're choosing a different path. So we're all familiar with the tailwinds and the other factor that's been contracting somewhat; and essentially, we're simply going to disrupt the market by combining our agentic capabilities and expertise with our proprietary data. That covers the IP side. On the A&G side, momentum is building too, thanks to the new Web of Science Research Intelligence, a new Alma Specto, and, clearly, Nexus Connect. Plus some of the fresh innovation emerging from the A&G product hubs. Optimistic about both.

George Tong

analyst
#13

Good morning, and thanks. I'd like to dig deeper into how transactional revenue has been performing. How much of the drop in transactional revenue would you attribute to industry-wide dynamics, and how much to company-specific execution issues? And why are you confident that transactional revenue can follow a path toward better results?

Matti Shem Tov

executive
#14

I'll begin, then pass things to Jonathan. The direction we're taking is something I'd call my playbook, or the playbook we've applied within the VCP — namely, shifting away from transactions. As we entered this VCP, certain businesses were fully divested, such as the one-time books, the one-time files, and the real-world data. Those exits happened quickly and completely. However, with the Life Sciences divestiture, we're also handing off some Life Sciences pieces at a somewhat higher level. That portion is transactional. A remaining slice of transactional business will continue with us, and it backs the one-time piece we previously had. Yet even inside that transactional business, there are still operations we're eager to convert into subscription offerings. One straightforward illustration: the batch files of Web of Science, which will steadily be lifted toward our subscription rate as we move through and past 94%, 92%. Now I'll turn it over to Jonathan for additional details on the quarter.

Jonathan Collins

executive
#15

Yes. Thank you, Matti. I'll add a bit of a different perspective regarding the quarter, George. Our organic figures for Q2 continue to include the Life Sciences segment. An agreement wasn't finalized by us until the quarter had already ended. However, that unit did face certain challenges during the period, especially on the transactional side. As Matti mentioned, we've been aiming to shift a number of those items toward subscription—that's one component of it—yet we also simply encountered some difficulties within Life Sciences. Regarding the remaining two segments, sure, results can fluctuate from one quarter to the next. We were aware that in Q2 we had cycled past a few items across both of those units, and those would create something of a drag. Still, we anticipate that situation will improve during the latter half of the year; our visibility there is stronger. This is accounted for in our guidance for the entire year. Transactional will decline modestly compared with the prior year. Nevertheless, I believe we'll observe some gains on that front in the back half. I appreciate the questions, George.

Adam Parrington

analyst
#16

Hi. Adam Parrington here, filling in for Shlomo. Did any particular client possibly affect the Life Sciences business and cause that revenue drop through the sort of transactional movement?

Jonathan Collins

executive
#17

Yeah. Appreciate you asking. No. Nothing stands out as discrete or specific, as I said. Matti mentioned that we've focused for roughly the past year on really delivering solid subscriptions so that some transactional business migrates away from it. So that's definitely one element, but there's nothing specific we'd call out client by client. Beyond simply some headwinds on the transactional side in that area.

Adam Parrington

analyst
#18

All right. When the purchaser of the Life Sciences division made the deal public, did they know how things had gone in the second quarter? I'm simply trying to confirm what might set something off — a MAC clause, that kind of thing.

Jonathan Collins

executive
#19

No. To be clear, nothing reaches that magnitude, and no, that process is unfolding precisely the way we anticipated. We went through the process to get to an agreement, and every approval needed is customary, and we anticipate those happening over the next few months, and we anticipate completion prior to the year's end.

Adam Parrington

analyst
#20

Thanks.

Matti Shem Tov

executive
#21

To wrap up, let me go over the main points once more. The picture right now is extremely clear; the foundations are set for us to speed up organic growth, and we'll keep honoring our pledge to create lasting value for shareholders. We appreciate your participation.

Operator

operator
#22

This concludes today's call. Thank you for attending. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Clarivate Plc transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Clarivate Plc earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Clarivate Plc or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.